Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly

This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

Garraway joins from Eli Lilly. Roche’s chief medical officer and head of global product development, Sandra Horning, will retire later this year after five years in the role. ... Her replacement has already been lined up. A statement from Roche’s

Latest news

More from news
Approximately 84 fully matching, plus 573 partially matching documents found.

Latest Intelligence

  • The fight for affordable insulin The fight for affordable insulin

    The world’s three biggest insulin manufacturers are Novo Nordisk, Sanofi and Eli Lilly. ... Lilly’s authorised generic. One company, Eli Lilly, has responded to the pleas for more affordable insulins, and launched a half price ‘authorised

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Since 2012, AC Immune has partnered tau assets with Roche’s Genentech, Johnson &Johnson and Eli Lilly. ... Sosei Heptares’ work on M1 falls into the latter category. Eli Lilly took an M1 agonist, xanomeline, into phase 3 in the 1990s and emerged with

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    EPAD combines knowledge and expertise from 39 European partner organisations across multiple sectors, including most of the big pharma companies involved in Alzheimer’s research (including Amgen, Janssen and Lilly, among ... Last month, Johnson

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Developed in partnership with Eli Lilly, it has already presented positive phase 3 results, with more expected in the first half of 2019, with filings expected shortly afterwards.

  • The good, the bad and the ugly The good, the bad and the ugly

    Pfizer ultimately lost. Patent expiries also led to large declines in CNS sales at Teva (-17%) and Eli Lilly (-27.5%).

More from intelligence
Approximately 4 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 30 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics